Table 2 Comparison of the treatment for COVID-19 between the 1st–5th wave group and the 6th wave group
From: Characteristics of the 6th Japanese wave of COVID-19 in hemodialysis patients
Treatment, n (%) | 1st–5th wave group | 6th wave group | p values |
|---|---|---|---|
Neutralizing antibody therapy | 7 (14.9) | 40 (75.5) | < 0.0001 |
Casirivimab/Imdevimab | 7 (14.9) | 0 (0) | 0.004 |
Sotrovimab | 0 (0) | 40 (75.5) | < 0.0001 |
Antiviral therapy | |||
Molnupiravir | 0 (0) | 47 (88.7) | < 0.0001 |
Remdesivir | 6 (12.8) | 12 (22.6) | NS |
Immunosuppressive therapy | |||
Dexamethasone | 25 (53.2) | 3 (5.7) | < 0.0001 |
Anticoagulation therapy | |||
Heparinization | 22 (46.8) | 7 (13.2) | < 0.001 |